Company intelligence / Profile preview

Animate Biosciences

Alameda, California, United States

Ownership: Private
Development stage: Other

Overview

Animate Biosciences has developed two leading peptide candidates that have demonstrated effectiveness in halting or reducing fibrosis in human skin, lung, cardiac, and liver cells. In vivo results for one compound show reduction of fibrosis and abnormal cell growth. The company aims to finalize a lead candidate and complete IND-enabling studies for an orphan dermatology indication by 2025

Therapeutic areas: DermatologyOther
Modalities: PeptidesAmino acid-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

MBb32

Preclinical

Beyond the preview

Go deeper on Animate Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Animate Biosciences.

Explore the full profile